Rejuran and Skinvive are both called "skin boosters," but they work through fundamentally different mechanisms, target different layers of skin function, and sit in entirely different regulatory categories in the United States. The comparison is worth making precisely because the overlap in marketing language — glow, hydration, skin quality — obscures how different these products actually are.
Skinvive by Juvéderm is an FDA-approved hyaluronic acid microdroplet injectable indicated for improving cheek skin smoothness in adults over 21. Rejuran is a polynucleotide injectable derived from salmon DNA, widely used in South Korea and expanding into Europe, but not FDA-approved for injection in the United States. That regulatory distinction is not a footnote — it changes what a patient can legally access and what evidence supports the claims.
What Skinvive actually is
Skinvive by Juvéderm (Allergan/AbbVie) received FDA approval in May 2023 as the first and only hyaluronic acid intradermal microdroplet injection indicated to improve skin smoothness of the cheeks in adults over 21 (FDA PMA P110033S059).
It is a modified hyaluronic acid formulation — less cross-linked than traditional Juvéderm fillers — designed to spread through the dermis rather than create structural volume. It is injected as microdroplets across the cheek area using a specific injection protocol. It contains lidocaine to reduce discomfort.
The pivotal clinical trial (NCT03728309) was a randomized, evaluator-blinded, controlled study. Key results from the FDA Summary of Safety and Effectiveness Data (SSED):
- 58% of treated participants achieved a ≥1-point improvement on the Allergan Cheek Smoothness Scale (ACSS) at 1 month
- 56% maintained that improvement at 6 months
- 72% were satisfied with how hydrated their skin looked at 6 months (vs. 24% at baseline)
- 63% were satisfied with how radiant their skin looked at 6 months (vs. 11% at baseline)
- Mean increase in skin hydration was 2.35 units vs. 0.11 for untreated control at 1 month
The device is approved for all Fitzpatrick skin types I–VI. Common side effects were injection-site reactions (redness, swelling, lumps/bumps, bruising), mostly mild to moderate and resolving within 7 days. As of 2026, AbbVie has submitted a supplemental PMA for treatment of horizontal neck lines, supported by Phase III data.
Skinvive is available at licensed injector practices across the United States. National average cost is approximately $522–$1,151 per treatment session, with two syringes being the typical treatment volume.
What Rejuran actually is
Rejuran (PharmaResearch, South Korea) is a polynucleotide (PN) injectable derived from salmon DNA — specifically polydeoxyribonucleotide (PDRN) fragments that are highly purified and formulated for intradermal injection.
The mechanism is regenerative rather than hydrating. PN activates fibroblasts, stimulates collagen and elastin production, improves microcirculation, and supports tissue repair at the cellular level. A 2024 review in the Journal of Cosmetic Dermatology (PMC11560330) summarized the evidence for polynucleotides in aesthetic medicine, noting their role in activating fibroblasts, promoting cell turnover, improving skin elasticity, and accelerating wound healing.
Rejuran has been the dominant skin booster in South Korea since approximately 2014. It is approved under the EU Medical Device Regulation (MDR) through a distribution partnership with VIVACY covering 22 European countries. It is the only PN product currently approved under the EU MDR framework.
In the United States, no PN or PDRN injectable is FDA-approved for cosmetic use. This includes Rejuran, Nucleofill, Plinest, and all similar products. Rejuran is available in the US only as a topical serum (marketed as Rejuran Healing Essence or c-PDRN) applied during or after microneedling — not as an injectable.
Mechanism comparison: repair vs. hydration
This is the core distinction, and it is not subtle.
| Feature | Skinvive | Rejuran |
|---|---|---|
| Active ingredient | Modified hyaluronic acid | Polynucleotides (salmon DNA–derived PDRN) |
| Primary mechanism | Hydration — attracts and binds water in the dermis | Regeneration — activates fibroblasts, stimulates collagen/elastin |
| What it targets | Skin smoothness, hydration, surface glow | Skin repair, barrier function, texture, elasticity |
| Onset | Immediate to 2 weeks | Gradual, 2–6 weeks |
| Duration | ~6 months (label) | 4–6 months (clinical literature, variable) |
| FDA status (US) | Approved (PMA, 2023) | Not approved for injection; topical serum only |
| Injection technique | Microdroplet intradermal | Serial injection or combined with microneedling |
| Volume effect | None (not a filler) | None |
| Contains lidocaine | Yes | Depends on formulation |
Skinvive works by placing hyaluronic acid into the dermis where it binds water. The result is immediate improvement in skin hydration and smoothness — think of it as an injectable moisturizer. It does not stimulate collagen production in a meaningful way and does not repair damaged skin.
Rejuran works by delivering polynucleotide fragments that signal fibroblasts to increase collagen and elastin synthesis. The result is gradual improvement in skin texture, elasticity, and barrier function over weeks. It does not provide the immediate hydrating "glow" that HA products deliver.
They are not interchangeable. They are not competitors doing the same thing with different branding. A patient choosing between them should be deciding between hydration-focused treatment (Skinvive) and repair-focused treatment (Rejuran) — not between two products in the same category.
The regulatory gap that matters
Skinvive has FDA approval with a specific indication, a published SSED, a registered clinical trial, and post-market surveillance requirements. Its safety and effectiveness data are publicly available on accessdata.fda.gov.
Rejuran has no FDA approval for injection in the United States. The clinical evidence supporting Rejuran comes primarily from Asian clinical settings — a 218-subject open-label study, the Pak Phase III trial, and various institutional studies conducted in Korea. These studies are legitimate, but they were not conducted under FDA oversight, and they have not been submitted to the FDA as part of a registration package.
This does not mean Rejuran is unsafe. It means the level of regulatory scrutiny and the strength of the evidence base are different. Patients in Korea or Europe may access Rejuran injection through properly regulated channels. Patients in the US cannot — legally — receive Rejuran as an injectable. Any US clinic offering "Rejuran injection" is operating outside the FDA's current framework.
The topical Rejuran Healing Essence (c-PDRN serum) applied during microneedling is a different product category — cosmetic, not injectable — with a different evidence base.
Cost comparison
- Skinvive (US): $522–$1,151 per treatment session (typically 2 syringes). Results last approximately 6 months. Annual maintenance: ~2 sessions.
- Rejuran (Korea/Europe): Roughly $300–$800 per session depending on market and clinic. Typically 2–3 sessions recommended initially, then maintenance every 4–6 months.
Direct cost comparison is difficult because the products are available in different markets, but Skinvive is generally more expensive per session in the US than Rejuran is per session in Korea.
Who is each product for?
Skinvive is the better fit when:
- You want improved skin smoothness and hydration on the cheeks
- You are in the US and want an FDA-approved product
- You want visible results quickly (within 2 weeks)
- You want a treatment with published FDA clinical trial data
- Your primary concern is dullness, dryness, or fine surface lines
Rejuran is the better fit when:
- You want skin repair and regeneration, not just hydration
- You have acne scarring, thin skin, or compromised skin barrier
- You are in Korea, parts of Europe, or another market where Rejuran injection is approved
- You are willing to wait 2–6 weeks for results to develop
- Your primary concern is texture, elasticity, or post-procedure recovery
Neither is a good fit when:
- You need structural volume correction — these are not fillers
- You have active skin infection or inflammation at the injection site
- You are pregnant or breastfeeding (standard precaution for injectable skin treatments)
- You have a known allergy to HA products (Skinvive) or to the specific PN formulation (Rejuran)
- You expect dramatic, single-session transformation
Rejuran product variants
Rejuran is not a single product. The line includes several formulations optimized for different uses:
- Rejuran Healer — the original PN injectable for full-face skin repair and regeneration
- Rejuran I — a lighter formulation designed specifically for the under-eye area, where skin is thinnest and most delicate
- Rejuran HB — a hybrid formulation combining PN with hyaluronic acid for both repair and hydration in a single product (sometimes called Rejuran HB+)
The variant selected affects what the treatment targets and how it feels during injection. Rejuran I for under-eye rejuvenation and Rejuran HB for combined repair-hydration are the two most common clinical selections after the base Healer product. None of these variants change the FDA regulatory status in the US — they remain unapproved for injection.
Can they be combined?
In markets where both are available, some providers sequence Rejuran and HA-based skin boosters in the same treatment plan — Rejuran for repair over weeks, followed by an HA product for immediate hydration and glow. Korean clinics frequently combine Rejuran I (under-eye repair) with Skinvive (overall hydration) in a single session. There is no published head-to-head study of this combination protocol. The logic is mechanistically plausible (repair + hydrate), but the evidence for superiority over either product alone is not established.
What to ask your provider
Before receiving either product:
- Is this product FDA-approved for injection? If the answer is no and you are in the US, ask what regulatory pathway the product is being used under.
- What clinical evidence supports the specific claims being made? Ask for published studies, not testimonials.
- What is the total cost, including any recommended touch-up sessions? Skin booster results are not permanent.
- What are the common side effects, and how long do they last?
- How many sessions are recommended, and what is the maintenance schedule?
- Is this product appropriate for my skin type and skin concerns?
Sources
- FDA Premarket Approval (PMA) P110033S059 — Skinvive by Juvéderm. accessdata.fda.gov
- FDA Summary of Safety and Effectiveness Data (SSED), Skinvive by Juvéderm. accessdata.fda.gov
- AbbVie press release, FDA approval of Skinvive by Juvéderm, May 15, 2023. news.abbvie.com
- Polynucleotides in Aesthetic Medicine: A Review of Current Evidence, Journal of Cosmetic Dermatology, 2024. PMC11560330
- FDA Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. fda.gov
- American Board of Cosmetic Surgery, Juvéderm Skinvive FDA approval summary. americanboardcosmeticsurgery.org
- Salmon DNA (PDRN) in Skincare: What the Evidence Actually Shows, iGlowly editorial review, 2026. iglowly.com
